ClinicalTrials.Veeva

Menu

Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)

U

University Hospital Muenster

Status

Enrolling

Conditions

Major Depressive Disorder

Treatments

Drug: Antidepressant

Study type

Observational

Funder types

Other

Identifiers

NCT05537558
University_of_Muenster_PROMPT

Details and patient eligibility

About

Major depressive disorder (MDD) is the most common psychiatric disease worldwide with a huge socio-economic impact. Pharmacotherapy represents the first-line treatment choice; however, only about one third of patients respond to the first trial and about 30% are classified as treatment-resistant depression (TRD). TRD is associated with specific clinical features and genetic/gene expression signatures. To date, single sets of markers have shown limited power in response prediction. The aim of this project is the development of a precision medicine algorithm that would help early detection of non-responder patients, who might be more prone to later develop TRD.

In this phase of the project a naturalistic cohort of 300 MDD patients will be recruited. The data collected will be used to assess, in real-world conditions, the capability of an innovative algorithm (integrating clinical, omics and gender data of other 300 patients con MDD) to predict the treatment outcomes. This project represents a proof-of-concept study. The obtained results will provide information about the feasibility and usefulness of the proposed approach, with the perspective of designing future clinical trials in which algorithms could be tested as a predictive tool to drive decision making by clinicians, enabling a better prevention and management of MDD resistance.

Enrollment

300 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • A current diagnosis of moderate to severe MDD according to the DSM-IV was confirmed using the SCID-I diagnostic scale

Exclusion criteria

  • Mental retardation or cognitive disorder
  • A lifetime history of schizophrenic, schizoaffective, or bipolar disorder Substance abuse in the last 3 months
  • Personality disorders, substance abuse, alcohol abuse, obsessive compulsive disorder, post-traumatic stress disorder, as primary diagnosis
  • Comorbidity with eating disorders
  • Substance or alcohol dependence

Trial contacts and locations

1

Loading...

Central trial contact

Alessandra Minelli, Dr; Bernhard T. Baune, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems